b. Epinephrine.
2. Miotics, direct acting.
a. Acetylcholine.
b. Carbachol.
c. Pilocarpine.
3. Miotics, cholinesterase inhibitors.
b. Echothiophate.
c. Isoflurophate.
d. Physostigmine.
4. Topical beta-adrenergic blocking agents.
a. Betaxolol.
b. Carteolol HCl.
c. Levobunolol.
d. Metipranolol HCl.
e. Timolol.
5. Oral carbonic anhydrase inhibitors.
a. Acetazolamide.
b. Dichlorphenamide.
c. Methazolamide.
(m) Any drug or device that is used for an ophthalmic therapeutic purpose and that is the subject of a new drug application approved by the food and drug administration under section 505 (c) (1) of the federal food, drug and cosmetic act, 21 USC 355, as amended. (n) Any drug or device that is used for an ophthalmic therapeutic purpose and that is generally exempt from the new drug application approval requirement contained in section 505 of the federal food, drug and cosmetic act, 21 USC 355, as amended. (o) Any drug or device that is used for an ophthalmic therapeutic purpose and that is certified by the food and drug administration pursuant to section 507 (a) of the federal food, drug and cosmetic act, 21 USC 357, or is exempt from certification under section 507 (c) of the act, as amended. (3) A licensed optometrist authorized to use therapeutic pharmaceutical agents may dispense a contact lens that delivers therapeutic pharmaceutical agents that are permitted under sub. (2).
Section 2. Effective Date. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats., of CR 19-027, Opt 6, relating to diagnostic and therapeutic pharmaceutical agents. ------------------------------------------------------------------------------------------------------------
(END OF TEXT OF RULE)
------------------------------------------------------------------------------------------------------------
